Fulgent Genetics Under Investigation for Securities Law Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy FLGT?
Source: Globenewswire
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025 on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could expose the company to legal liabilities and compensation risks.
- Investor Loss Focus: The investigation has drawn attention from investors who suffered losses in Fulgent securities, potentially prompting more investors to seek legal remedies to recover losses, further affecting the company's reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 16.130
Low
30.00
Averages
32.50
High
35.00
Current: 16.130
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulgent Genetics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fulgent Genetics will announce its Q1 2026 financial results before the market opens on May 1, 2026, reflecting the company's ongoing development in technology-based and laboratory services.
- Investor Conference Call: Management will host a conference call at 8:30 AM ET on the same day to discuss the financial results and answer investor questions, enhancing transparency and investor confidence.
- Business Transformation Strategy: Fulgent is transitioning from a traditional diagnostic business to a fully integrated precision medicine company, focusing on developing drug candidates for various cancers using a novel nanoencapsulation and targeted therapy platform to improve drug efficacy.
- Laboratory Services Overview: The company's laboratory services include technical laboratory and testing services, along with professional interpretation of results by licensed physicians, showcasing its expertise and competitiveness in the healthcare service sector.
See More
Fulgent Genetics Under Investigation for Securities Law Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025 on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could expose the company to legal liabilities and compensation risks.
- Investor Loss Focus: The investigation has drawn attention from investors who suffered losses in Fulgent securities, potentially prompting more investors to seek legal remedies to recover losses, further affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Drop: The company's fourth-quarter revenue declined sequentially, reflecting weak business growth that may raise investor concerns about future performance, potentially impacting stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Fulgent violated federal securities laws, and if confirmed, this could lead to legal liabilities and financial losses for the company, further eroding shareholder confidence.
- Investor Loss Risk: Investors who suffered losses in the company's securities may participate in litigation, increasing the legal risks faced by the company and affecting its market reputation and future financing capabilities.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected guidance for 2026 in its February 27, 2026 press release regarding its 2025 Q4 and full-year results, indicating significant business challenges due to its largest customer moving substantial work in-house.
- Stock Price Volatility: Following this news, Fulgent's stock price plummeted by $9.43, or approximately 38.1%, from $24.76 on February 26, 2026, to $15.33 on February 27, reflecting strong market concerns about the company's future outlook.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Fulgent and its senior management, and while no lawsuit has been filed yet, the situation could have profound implications for the company's reputation and shareholder rights.
- Investor Rights Protection: The law firm is urging investors who purchased or acquired Fulgent securities to provide information for potential legal action, highlighting the importance of investor involvement and the avenues for legal recourse in such investigations.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected financial results for Q4 and full year 2025 on February 27, 2026, indicating that 2026 guidance reflects the impact of its largest customer moving significant work in-house, leading to decreased investor confidence.
- Stock Price Volatility: Following the earnings report, Fulgent's stock price plummeted from $24.76 on February 26, 2026, to $15.33, marking a 38.1% decline, which reflects market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into potential violations of federal securities laws by Fulgent and its senior management; while no lawsuit has been filed yet, the ongoing investigation could impact the company's reputation and shareholder interests.
- Investor Action Advisory: The law firm advises investors who purchased Fulgent securities or have relevant information to contact them to discuss their rights, highlighting the potential risks associated with the company's legal issues and the strategies investors might consider.
See More
Fulgent Genetics Completes Acquisition of Bako and StrataDx
- Acquisition Completion: Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash, which is expected to enhance its market position in pathology and dermatopathology, driving future revenue growth.
- Asset Integration Benefits: This acquisition allows Fulgent to integrate Bako's specialized laboratory testing services with StrataDx's advanced dermatopathology offerings, thereby enhancing its technical capabilities and service range, further solidifying its competitive edge in precision medicine.
- Market Expansion Potential: The addition of Bako and StrataDx enables Fulgent to offer a more comprehensive range of pathology services, addressing the growing market demand, particularly in cancer diagnostics and treatment, which is expected to attract more clients and increase market share.
- Strategic Development Direction: This acquisition aligns with Fulgent's strategic goal of transforming into a fully integrated precision medicine company, demonstrating its commitment to achieving long-term growth through technological innovation and market expansion.
See More
Fulgent Genetics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fulgent Genetics will announce its Q1 2026 financial results before the market opens on May 1, 2026, reflecting the company's ongoing development in technology-based and laboratory services.
- Investor Conference Call: Management will host a conference call at 8:30 AM ET on the same day to discuss the financial results and answer investor questions, enhancing transparency and investor confidence.
- Business Transformation Strategy: Fulgent is transitioning from a traditional diagnostic business to a fully integrated precision medicine company, focusing on developing drug candidates for various cancers using a novel nanoencapsulation and targeted therapy platform to improve drug efficacy.
- Laboratory Services Overview: The company's laboratory services include technical laboratory and testing services, along with professional interpretation of results by licensed physicians, showcasing its expertise and competitiveness in the healthcare service sector.
See More
Fulgent Genetics Under Investigation for Securities Law Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025 on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could expose the company to legal liabilities and compensation risks.
- Investor Loss Focus: The investigation has drawn attention from investors who suffered losses in Fulgent securities, potentially prompting more investors to seek legal remedies to recover losses, further affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Drop: The company's fourth-quarter revenue declined sequentially, reflecting weak business growth that may raise investor concerns about future performance, potentially impacting stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Fulgent violated federal securities laws, and if confirmed, this could lead to legal liabilities and financial losses for the company, further eroding shareholder confidence.
- Investor Loss Risk: Investors who suffered losses in the company's securities may participate in litigation, increasing the legal risks faced by the company and affecting its market reputation and future financing capabilities.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected guidance for 2026 in its February 27, 2026 press release regarding its 2025 Q4 and full-year results, indicating significant business challenges due to its largest customer moving substantial work in-house.
- Stock Price Volatility: Following this news, Fulgent's stock price plummeted by $9.43, or approximately 38.1%, from $24.76 on February 26, 2026, to $15.33 on February 27, reflecting strong market concerns about the company's future outlook.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Fulgent and its senior management, and while no lawsuit has been filed yet, the situation could have profound implications for the company's reputation and shareholder rights.
- Investor Rights Protection: The law firm is urging investors who purchased or acquired Fulgent securities to provide information for potential legal action, highlighting the importance of investor involvement and the avenues for legal recourse in such investigations.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected financial results for Q4 and full year 2025 on February 27, 2026, indicating that 2026 guidance reflects the impact of its largest customer moving significant work in-house, leading to decreased investor confidence.
- Stock Price Volatility: Following the earnings report, Fulgent's stock price plummeted from $24.76 on February 26, 2026, to $15.33, marking a 38.1% decline, which reflects market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into potential violations of federal securities laws by Fulgent and its senior management; while no lawsuit has been filed yet, the ongoing investigation could impact the company's reputation and shareholder interests.
- Investor Action Advisory: The law firm advises investors who purchased Fulgent securities or have relevant information to contact them to discuss their rights, highlighting the potential risks associated with the company's legal issues and the strategies investors might consider.
See More
Fulgent Genetics Completes Acquisition of Bako and StrataDx
- Acquisition Completion: Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash, which is expected to enhance its market position in pathology and dermatopathology, driving future revenue growth.
- Asset Integration Benefits: This acquisition allows Fulgent to integrate Bako's specialized laboratory testing services with StrataDx's advanced dermatopathology offerings, thereby enhancing its technical capabilities and service range, further solidifying its competitive edge in precision medicine.
- Market Expansion Potential: The addition of Bako and StrataDx enables Fulgent to offer a more comprehensive range of pathology services, addressing the growing market demand, particularly in cancer diagnostics and treatment, which is expected to attract more clients and increase market share.
- Strategic Development Direction: This acquisition aligns with Fulgent's strategic goal of transforming into a fully integrated precision medicine company, demonstrating its commitment to achieving long-term growth through technological innovation and market expansion.
See More
